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ABSTRACT We determined the susceptibilities of 57 Talaromyces marneffei strains to
anidulafungin, itraconazole, voriconazole, and posaconazole with MICs of 2 to 8,
0.002 to 0.004, 0.016 to 0.063, and 0.001 to 0.002 g/ml by broth microdilution and
32, 0.002 to 0.008, 0.002 to 0.008, and 0.002 g/ml by Etest, respectively, at
yeast phase; MICs at mycelial phase for anidulafungin and posaconazole were 1 to 2
and 0.004 to 0.063 g/ml, respectively. The results suggest promising activities of
posaconazole. Etest can be used for testing of azoles against T. marneffei.
KEYWORDS Etest, Penicillium, Talaromyces marneffei, anidulafungin, itraconazole,
posaconazole, susceptibility, voriconazole
Talaromyces marneffei, previously named Penicillium marneffei, is the most importantthermal dimorphic fungus causing systemic mycosis (penicilliosis) in southeast Asia
(1–3). In recent decades, penicilliosis has emerged in HIV-infected and other immuno-
compromised patients in various countries (3–6). Since the disease carries a high
mortality rate and is associated with relapse, ﬁnding ways to improve diagnosis and
treatment is crucial (7, 8). Moderate or severe penicilliosis is often treated with ampho-
tericin B for 2 weeks, followed by maintenance with prolonged itraconazole to prevent
relapse. Primary prophylaxis with itraconazole in susceptible patients from areas in
which the disease is endemic is also recommended.
T. marneffei is known to be susceptible in vitro to various antifungal agents,
including amphotericin B, itraconazole, and terbinaﬁne (9, 10). Besides itraconazole,
voriconazole is an effective azole that is well tolerated for the treatment of penicilliosis
(9, 11). Posaconazole, a triazole with broad antifungal activities, may offer additional
advantages over itraconazole and voriconazole, especially in critically ill patients with
organ dysfunction, because no renal or hepatic dosage adjustment is required. Al-
though excellent in vitro activity of posaconazole against one strain of T. marneffei has
been reported (12), no systematic evaluation on its activity against T. marneffei has
been performed. While echinocandins are another new class of antifungals potentially
effective against diverse fungi, only one report has described the potential activity of
anidulafungin against three T. marneffei strains (13). Moreover, it remains uncertain if
Etest is a reliable alternative to reference broth microdilution methods for T. marneffei
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susceptibility testing. Therefore, using broth microdilution and Etest methods, we
attempted to assess the potential activities of posaconazole against T. marneffei
compared to those of itraconazole, voriconazole, and anidulafungin.
A total of 57 nonduplicated T. marneffei strains, including 56 strains isolated from
blood (n  48), lymph node (n  1), bone marrow (n  2), skin biopsy specimen (n 
1), sputum (n  1), or pleural (n  1) or bronchoalveolar lavage (n  2) ﬂuid cultures
of patients with culture-documented penicilliosis and the type strain ATCC 18224
isolated from a bamboo rat, were included. All T. marneffei strains were identiﬁed by
conventional phenotypic tests and sequencing of three housekeeping genes (mannose
phosphate isomerase [MPI], plasma membrane H ATPase [PM-ATPase], and pyruvate
kinase [PK]) and by matrix-assisted laser desorption ionization–time of ﬂight mass
spectrometry as described previously (7). Yeast and mycelial cultures of T. marneffei
were grown on Sabouraud dextrose agar (SDA) (Oxoid, Cambridge, United Kingdom) as
described previously with modiﬁcations (14). A single colony was inoculated into RPMI
1640 medium and incubated at 37°C for yeast cultures or 25°C for mycelial cultures.
Candida parapsilosis ATCC 22019 and Candida krusei ATCC 6258 were used as control
strains (breakpoints of controls according to CLSI M27-S4 [15]) in each run.
Since no existing guidelines were available for susceptibility testing of T. marneffei,
broth microdilution assays were performed according to CLSI methods for testing
yeasts or ﬁlamentous fungi but with a prolonged incubation time of 72 h (yeast
cultures) or 96 h (mycelial cultures) (16, 17). Brieﬂy, stock solutions of anidulafungin
(Pﬁzer, NY, USA), itraconazole (Janssen Pharmaceuticals, NJ, USA), voriconazole (Pﬁzer),
and posaconazole (Schering-Plough, NJ, USA) were prepared from standard powder by
dissolving them in 100% dimethyl sulfoxide (DMSO) and were serially 2-fold diluted in
RPMI 1640 medium (Life Technologies, Carlsbad, CA, USA). Drugs were inoculated onto
96-well microplates, at 100 l, followed by addition of 100 l of T. marneffei suspension
(1  103 to 5  103 CFU/ml for yeast and 0.4  104 to 5  104 CFU/ml for conidia) in
RPMI 1640 medium, diluted from stock suspensions of 0.5 McFarland standard for
yeasts, or 1.0 McFarland standard for conidia. Final drug concentration ranges were
0.001 to 2 g/ml for itraconazole, 0.0005 to 0.5 g/ml for voriconazole, 0.008 to 8
g/ml for anidulafungin, and 0.0002 to 0.25 g/ml for posaconazole. These ﬁgures
were mathematically rounded to three or four digits after the decimal point for ease of
interpretation. Etest was performed using RPMI 1640 agar with T. marneffei yeast
suspensions of 0.5 McFarland standard according to manufacturer instructions (18).
Etest using mycelial forms was not performed, because growth was too slow to allow
testing. The following Etest strips were used: anidulafungin, itraconazole, posaconazole,
and voriconazole (concentration ranges were 32 to 0.002 g/ml for anidulafungin,
itraconazole, posaconazole, and voriconazole) (bioMérieux, Marcy-l’Étoile, France). MICs
or minimal effective concentrations (MECs) (for anidulafungin against mycelial cultures)
were determined according to CLSI guidelines for the microdilution method (16, 17)
and manufacturer instructions for the Etest (18). The percent MIC agreement (2 2-fold
dilutions) between broth microdilution and Etest was calculated as described previ-
ously (19). MICs determined by Etest that fell between the 2-fold dilutions of broth
microdilution MICs were elevated to the next drug concentration so that they matched
the 2-fold dilution scheme.
The MICs as determined by the broth microdilution and Etest methods are summa-
rized in Table 1. All MICs of control strains were within the expected range for each
strain. When the broth microdilution method was used, the MICs of the azoles against
T. marneffei yeast phase were very low (ranges, 0.002 to 0.004, 0.016 to 0.063, and 0.001
to 0.002 g/ml for itraconazole, voriconazole, and posaconazole, respectively). In
contrast, the MICs of anidulafungin against T. marneffei yeast phase were much higher
(2 to 8 g/ml). The results suggest that the azoles itraconazole, voriconazole, and
posaconazole possessed good activities against the 57 strains of T. marneffei, whereas
anidulafungin had only moderate activities against T. marneffei at yeast phase. While
yeast forms represent the infective stage of T. marneffei in vivo and are easier and safer
to handle in clinical laboratories, we also attempted to assess the potential activities of
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posaconazole and anidulafungin against mycelial forms; we found MIC ranges of 0.004
to 0.063 g/ml and MEC ranges of 1 to 2 g/ml, respectively.
The Etest method revealed that the MICs of the azoles against T. marneffei yeasts
were also very low (ranges, 0.002 to 0.008 g/ml for itraconazole and voriconazole
and 0.002 g/ml for posaconazole). In contrast to the moderate activities of anidu-
lafungin demonstrated by broth microdilution assays, the MICs of anidulafungin by
Etest against all T. marneffei strains were 32 g/ml. The values for percent agreement
between the MICs by broth microdilution and the MICs by Etest against yeast forms are
shown in Table 1. For itraconazole and posaconazole, 100% agreement within two
2-fold dilutions was found. However, the percent agreement was lower for voriconazole
(31.58%) and anidulafungin (24.56%). Despite the low percent agreement for voricona-
zole, both methods demonstrated very low MICs, supporting the usefulness of Etest for
testing the azoles.
The present results show promising activities of posaconazole against the yeast and
mycelial phases of T. marneffei. Moreover, according to the broth microdilution and
Etest methods, the MIC50 of posaconazole against T. marneffei yeasts was the lowest
among the three tested azoles. While ﬂuconazole is known to have reduced activities
against T. marneffei yeasts (MIC range, 4 to 8 g/ml), itraconazole and voriconazole
usually possess good activities, with MICs usually 1 g/ml (9, 10, 20, 21). However,
MICs as high as 50 g/ml have been reported for itraconazole against yeast forms of T.
marneffei (22). While systematic studies evaluating the activities of posaconazole were
lacking, the present results are in line with those described in a previous case report in
which the potential activity of posaconazole (MIC, 0.001 g/ml) against the yeast phase
of a T. marneffei strain isolated from a Greek HIV-infected patient with travel history to
China was shown (12). As for the mycelial phase of T. marneffei, posaconazole also
exhibited good activities with very low MICs, consistent with previous ﬁndings on
itraconazole (21).
Etest methods may serve as a more convenient alternative to broth dilution for
susceptibility testing of azoles against T. marneffei. However, the performance of Etest
for determining the activities of anidulafungin and possibly other echinocandins re-
mains doubtful. Moreover, the apparent resistance of T. marneffei yeasts to anidula-
fungin by Etest and the relatively high MICs of anidulafungin by broth microdilution
against both yeast and mycelial forms suggest that anidulafungin is likely less active
TABLE 1 In vitro MIC determinations of four antifungals against 57 T. marneffei strains as
determined by broth microdilution and Etest methods
Antifungal and test method
MIC (g/ml)a
% MIC agreementbRange 50% 90%
Itraconazole
Broth microdilution (yeast) 0.002–0.004 0.004 0.004 100
Etest (yeast) 0.002–0.008 0.004 0.006
Voriconazole
Broth microdilution (yeast) 0.016–0.063 0.031 0.063 31.58
Etest (yeast) 0.002–0.008 0.003 0.006
Posaconazole
Broth microdilution (mycelia) 0.004–0.063 0.016 0.031
Broth microdilution (yeast) 0.001–0.002 0.002 0.002 100
Etest (yeast) 0.002 0.002 0.002
Anidulafungin
Broth microdilution (mycelia) 1–2c 1c 2c
Broth microdilution (yeast) 2–8 4 8 24.56
Etest (yeast) 32 32 32
a50% and 90%, MICs that inhibited 50% and 90% of the strains tested, respectively.
bPercentage of Etest MICs in yeast phase that were within 2 log2 dilutions of the broth microdilution
method MICs.
cMEC was used for anidulafungin against mycelial cultures according to CLSI guidelines (M38-A2).
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than the azoles against T. marneffei. In one of the few published studies on the activities
of echinocandins against T. marneffei, the authors claimed promising activities of
anidulafungin against three T. marneffei strains in mycelial phase, with MICs ranging
from 0.5 to 2 g/ml (13). In another report, micafungin possessed low activities, with
MICs ranging from 4 to 16 g/ml for yeast forms and 0.313 to 2 g/ml for mycelial
forms of T. marneffei (21). Although the MICs by broth microdilution against mycelial
phase were lower than those against yeast phase in this study, the values were still
relatively high compared to those of the azoles. Further studies should be performed
to better assess the potential activities of echinocandins for treatment of penicilliosis.
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